Share Name Share Symbol Market Type Share ISIN Share Description
4d Pharma Plc LSE:DDDD London Ordinary Share GB00BJL5BR07 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  8.30 29.86% 36.10 463,135 16:10:11
Bid Price Offer Price High Price Low Price Open Price
36.00 38.00 38.60 28.50 28.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -28.44 -36.17 24
Last Trade Time Trade Type Trade Size Trade Price Currency
16:09:23 O 11,960 36.10 GBX

4d Pharma (DDDD) Latest News

More 4d Pharma News
4d Pharma Takeover Rumours

4d Pharma (DDDD) Discussions and Chat

4d Pharma Forums and Chat

Date Time Title Posts
06/4/202015:024D Pharma 2018 - from Ј2 back up to Ј10+398
05/4/202020:104d Pharma164
08/3/202021:164D Pharma (DDDD) One to Watch 8

Add a New Thread

4d Pharma (DDDD) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all 4d Pharma trades in real-time

4d Pharma (DDDD) Top Chat Posts

4d Pharma Daily Update: 4d Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker DDDD. The last closing price for 4d Pharma was 27.80p.
4d Pharma Plc has a 4 week average price of 23.50p and a 12 week average price of 23.50p.
The 1 year high share price is 131p while the 1 year low share price is currently 23.50p.
There are currently 65,493,842 shares in issue and the average daily traded volume is 295,736 shares. The market capitalisation of 4d Pharma Plc is £24,036,240.01.
marketanalyst1: Howard Stanley Marks, the billionaire serial investor and founder of Oaktree Capital Management, once opined that: "When looking for the best stocks to buy, it pays to follow the money.” Indeed, investing alongside some of the world’s wealthiest can be very profitable. Take 4D Pharma for example; the London-listed pharmaceutical company (specialising in the development of live biotherapeutic products) currently boasts City heavyweight Richard Griffiths as its largest shareholder. The extremely well-heeled (estimated net worth of circa £300m) serial investor, who carved out a hugely successful business advising small and medium-sized companies, owns close to 14% of the company and is one of the most highly regarded investors in the UK. Known for his innate ability to unearth mispriced opportunities, Mr Griffiths is one of those high-net-worth investors who prefer to keep things pretty simple; invest in well-run companies, with significant growth potential, and that sport a substantial discount to NAV. Pretty simple. Thus, cue 4D Pharma. The Leeds-based pharmaceutical company, currently spearheading a revolutionary new class of medicines called Live Biotherapeutics, has four, advanced, clinical-stage programmes underway in immuno-oncology, IBS, asthma and IBD. However, there’s a problem. The recent stock market rout has given rise to a staggering, and wholly unwarranted, share price dislocation that, frankly, beggars belief. Here’s why; • On January 10, 2020, 4D Pharma had zero debt. • On January 10, 2020, 4D Pharma had cash and cash equivalents of circa £3.5 million (down from £12.9m at July 01, 2019). • On February 18, 2020, 4D Pharma raised gross proceeds of £22m at 50p per share. • On March 01, 2020, 4D Pharma had cash and cash equivalents of circa £23.5 million. • By March 18, 2020, 4D Pharma’s BOD had garnered some serious ‘skin in the game’; all three directors collectively owned 22% (24,091,936 shares) of the company! • On March 18, 2020, 4D Pharma delivered the FIRST global clinical confirmation of a live biotherapeutic product initiating a response in cancer patients; evidence of tumour shrinkage and no drug-related adverse events were observed. Overall, 51% reduction in target tumours was observed. • The company’s first significant readout (Blautix® Phase II interim analysis), which is likely to trigger a material share price re-rate, is expected within three weeks’ time (April – early Q2 2020). • The company’s second significant readout (MRx0518 Phase I/II combination study with Keytruda®), which is also likely to trigger a material share price re-rate, is expected within seven weeks’ time (around May 2020). So, with a current market cap of £26.5m (26p), and less cash of £23.5m, means the market is valuing the company’s incredibly advanced and highly promising stable of drug candidates at £3.5m! Yes, feel free to bark the unsavoury but apt remark, “What the ….!” And yes, the stock market is not always the perfect arbiter of value. However, for as sure as night follows day, the market will soon move to correct the gross mispricing. In the meantime, the recently-released clinical data for the company’s lead oncology candidate may help to explain why Griffiths, the BOD, Invesco, and Henderson continue to clutch onto their 14%, 22%, 8.5%, and 3% stakes respectively.
mustau: Unfortunately means nothing to the share price.
ch1ck: Steady buying of shares over the last week or so which is encouraging and the share price has risen. It feels like something is building, maybe a break out to the up side?Look at me being optimistic!
secret investor: I’m surprised that people don’t know about the WG deal. WG has agreed to buy the Woodford stake in many companies, including DDDD. This was reported on 25 October and caused the price spike on that date. The Sunday Times yesterday reported that WG is confident of raising the requisite funds by the end of the exclusivity period (31st Jan i.e. this Friday). The share price of SUPP (ex-WPCT) spiked up at 4:08pm today, which might suggest that news has leaked that the WG deal will complete. If so, the relevant Woodford companies (including DDDD) should get a rocket boost to their share price. If the deal doesn’t complete by Friday, WG may seek an extension to the exclusivity period. Otherwise the other bidders (at least three were interested) come back into play. I can’t see the Woodford stake in DDDD not being snapped up, it’s a great company with a fanstastic deal with Merck. It’s just a matter of time.
the stigologist: No. Fund Managers whose job is to liquidate holdings do not 'wait for news on stocks they are positive on'. They will let their dealers know they want to sell and tell them to get on with it. Ideally in line with volume but if needs be at whatever price they can get away with it. However that doesn't necessarily have to damage or impact the share price. Note for example the clearout transaction at ETX done in the 1s but the stock price didn't go below 2.5p and once overhang cleared went to 3-4p range.
secret investor: Agreed, Stig. The share price went from £1 to £10 on the back of Woodford's investments - then back down to £1 as the Woodford scandal hit. Once Woodford clears this is due a major re-rate, and not just on hope value this time - but rather the >$1bn deal with Merck. There may be no magic in 17 January (hence the "from") but the 4 November Sky News piece on the WG bid said that the deal would take "several weeks to conclude". It's possible that a deal is already done and will be announced on (or soon after) the winding-up commences. There is huge pressure to reimburse the LTEIF holders ASAP.
ch1ck: I'm just reviewing my holding and noted I have an unusually large holding in this stock so wanted to check there was still a reason to hold. looking back at previous announcements I thought I would repost this: Company has entered into a research collaboration and option to license agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics ("LBPs") for vaccines. Under the terms of the agreement 4D's proprietary MicroRx® platform will be paired with MSD's expertise in the development and commercialisation of novel vaccines, to discover and develop LBPs as vaccines in up to three undisclosed indications. 4D has the right, subject to certain conditions, to cause MSD to purchase $5 million in ordinary shares in 4D during the first 12 months of the collaboration. In addition to an upfront cash payment, for each indication, 4D will be eligible to receive up to $347.5 million in option exercise and development and regulatory milestone payments, plus tiered royalties on annual net sales of any licensed products derived from the collaboration. MSD will be responsible for development, manufacturing and commercialisation following the exercise of any of its exclusive options. This would indicate that the clock is ticking for 4D to get drugs through phase 2 and three and also Merck to pull the trigger if they want to buy options. Recent buys in the tens of millions would indicate that there is appetite for the stock and this could explode up on any good news or insider trading. Remember Woodford for all his failings did his research and bought in. (don't hold that against the stock) Finally I ran some overlays on the 1, 3 and 5year charts and it looks like the 50 day moving average is about to cross the 200 and will do this if the day price moves through 120p which I looks like a possibility. This is defiantly not a risk free stock but one I'm happy to hold and add to if the share price moves through 100p
ch1ck: Société Général decided to invest in just under 6.5 Million shares last week. This was done with the shares trading around these levels. Shares have retraced back to the same level with what seems to be low volume of shares sold.This would seem to indicate that shares will be in shorter supply meaning if we have another player looking to invest in 4D the share price will push up with support.The next few weeks will be very interesting. I have decided to take a fairly large position here
someuwin: 4D pharma plc (the "Company" or "4D") Trading Update 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, notes the recent fall in its share price, and confirms that it is not aware of any Company related matter which could be responsible for this price movement. The Board also confirms that all clinical study timelines continue to progress as expected.
someuwin: Article in Today's Shares Magazine. James Henderson from Lowland Investment Company... "...He also likes drug company 4D Pharma (DDDD:AIM) which he calls a well-funded company with drugs being tested and which has an attractive tie-up with pharma giant Merck. 'Sometimes stocks get overhyped and people get bored of them so the share price drifts. That's happened with 4D Pharma yet real progress is being made with its portfolio."
4d Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
4d Pharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200406 15:33:02